Toll-like Receptors

CAY10614 is a potent TLR4 antagonist that inhibits lipid A-induced activation of the TLR4 receptor, exhibiting an IC50 of 1.675 μM. This compound has demonstrated the ability to improve survival rates in mouse models of lethal endotoxin shock. CAY10614 is valuable for research applications investigating TLR4-mediated inflammatory responses and the development of therapeutic strategies targeting sepsis and other endotoxin-related conditions.

CPG-52364 is a TLR9 antagonist that exhibits inhibitory activity against TLR9 in the HEK293-hTLR9 cell line, with an IC50 value of 4.6 nM. This compound is valuable for research applications investigating immune response modulation, particularly in studies related to autoimmune diseases and inflammation. Its specificity for TLR9 makes it a useful tool for exploring the therapeutic potential of TLR modulation in various biological contexts.

CL097 hydrochloride is a potent agonist of Toll-like receptors 7 and 8 (TLR7/8) that activates pro-inflammatory cytokine production in macrophages. This compound also facilitates NADPH oxidase priming, leading to enhanced reactive oxygen species (ROS) generation upon fMLF stimulation. CL097 is valuable in research applications related to immune response and inflammation.

TLR8 Agonist 4 is a potent agonist targeting Toll-like receptor 8 (TLR8), demonstrating efficacy against both wild-type and drug-resistant HBV strains, including those resistant to lamivudine and entecavir. The compound exhibits IC50 values of 0.15 μM and 0.10 μM, respectively, highlighting its potential for use in antiviral research and therapeutic development against Hepatitis B virus.

TLR7 Agonist 12 is a potent TLR7 agonist and a purine nucleoside analog. This compound demonstrates significant antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms are mediated through the inhibition of DNA synthesis and the induction of apoptosis, making it valuable for research applications in cancer therapeutics and immune modulation studies.

SMU-L11 is a selective TLR7 agonist with an EC50 of 0.024 μM, which engages the MyD88 adapter protein to activate downstream NF-κB and MAPK signaling pathways. This compound significantly enhances immune cell activation in murine models, promoting the proliferation of CD4+ T and CD8+ T cells, leading to direct tumor cell lysis and inhibition of tumor growth. SMU-L11 is a valuable reagent for cancer research and can also be utilized for investigations into immune system-related diseases.

HCN-IN-1 is a TLR4 inhibitor and modulator of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, specifically targeting HCN2 and HCN4. It effectively inhibits TLR4-mediated signaling, evidenced by reduced alkaline phosphatase activity. HCN-IN-1 modulates HCN2 currents by shifting the voltage-dependent activation to hyperpolarized potentials and slowing activation kinetics, while also blocking currents through HCN4 channels. This compound demonstrates significant analgesic, anti-inflammatory, and anti-anginal properties, making it valuable for research into inflammatory pain, neuropathic pain, heart failure, and related inflammatory conditions.

Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions.